Sequoia Financial Advisors LLC Has $1.05 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Sequoia Financial Advisors LLC raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 42.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,758 shares of the medical research company’s stock after buying an additional 4,095 shares during the period. Sequoia Financial Advisors LLC’s holdings in Edwards Lifesciences were worth $1,049,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Advisors Asset Management Inc. increased its stake in Edwards Lifesciences by 0.3% in the first quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock valued at $5,127,000 after purchasing an additional 117 shares in the last quarter. Apollon Wealth Management LLC increased its stake in Edwards Lifesciences by 1.0% in the first quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company’s stock valued at $1,033,000 after purchasing an additional 119 shares in the last quarter. Geller Advisors LLC increased its stake in Edwards Lifesciences by 6.5% in the first quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock valued at $231,000 after purchasing an additional 120 shares in the last quarter. Legacy Wealth Asset Management LLC increased its stake in Edwards Lifesciences by 0.8% in the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after purchasing an additional 134 shares in the last quarter. Finally, KCM Investment Advisors LLC increased its stake in Edwards Lifesciences by 2.7% in the first quarter. KCM Investment Advisors LLC now owns 5,392 shares of the medical research company’s stock valued at $635,000 after purchasing an additional 142 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity

In other news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 1,715 shares of the firm’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.98, for a total transaction of $156,030.70. Following the transaction, the vice president now directly owns 17,213 shares in the company, valued at $1,566,038.74. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 over the last ninety days. 1.29% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Stifel Nicolaus upped their target price on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research note on Wednesday, February 7th. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Truist Financial upped their price target on shares of Edwards Lifesciences from $78.00 to $84.00 and gave the company a “buy” rating in a report on Friday, December 22nd. Finally, Mizuho upped their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $91.33.

Edwards Lifesciences Stock Performance

NYSE EW opened at $90.28 on Monday. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average price is $90.01 and its two-hundred day moving average price is $77.79. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12. The firm has a market capitalization of $54.34 billion, a P/E ratio of 39.25, a price-to-earnings-growth ratio of 4.47 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The company’s revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.64 earnings per share. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.